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Complexity of expression of the intermediate filaments
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Summary Six permanent human ovarian carcinoma cell lines (OVISE, OVTOKO, OVMANA and OVSAYO from clear cell adenocarcinoma,
and OVSAHO and OVKATE from serous papillary adenocarcinoma) were established from solid tumours. The cell lines have been in culture
for 5-8 years, the passage number varying from 62 to 246. Immunohistochemical analysis has shown that five of the six cell lines express at
least six cytokeratin (CK) polypeptides. OVISE and OVSAYO expressed CKs 6, 7, 8,18,19 and 15 and/or 16. OVTOKO was positive for CKs
7, 8,18,19 and 15 and/or 16. OVSAHO expressed CKs 6, 7, 8,14,18,19 and 15 and/or 16. OVMANA expressed CKs 6, 7, 8, 18,19, 20 and
15 and/or 16. OVKATE expressed CKs 6, 7, 8, 13, 17, 18, 19, 20 and 15 and/or 16. The expression of CK7, additional expression ofvimentin,
and clinical and histopathological findings enabled us to confirm that six cell lines had been established from primary ovarian cancers. Two of
the six cell lines were positive for CK20, although CK20 was not expressed in the original tumours. The heterotransplanted tumours produced
by CK20-positive cells also expressed CK20. This is the first report of ovarian carcinoma cell lines that express CK20 irrespective of their
histological type. CK20 has been found in all colon carcinoma cell lines, but only in the mucinous type of ovarian tumours. These new ovarian
carcinoma cell lines will therefore provide a relevant experimental system for elucidating the regulatory control mechanisms of intermediate
filament expression.
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The characteristics ofovarian cancer have been studied in primary
tumours and in established cell lines that provide a reproducible
source oftumour material (Buick et al, 1985; Horowitz et al, 1985;
Hill et al, 1987; Sheer et al, 1987; Wolfet al, 1987; Langdon et al,
1988; Niekerk et al, 1988; Crickard et al, 1989; Hills et al, 1989;
Wong et al, 1990; Mobus et al, 1992; Fuchtner et al, 1993;
Morimitsu et al, 1993; Van Den Berg-Bakker et al, 1993). The
characterization ofrelevant ovarian carcinoma cell lines is consid-
ered to be worthwhile for the investigation of their epithelial
nature and derivation, and to demonstrate no contamination with
fibroblasts. There have been only a few studies on the expression
of intermediate filament (IF) in ovarian cancer cell lines. The
cytokeratins (CKs) are known to be composed of a family of at
least 20 different polypeptides and to be distributed in both normal
and neoplastic tissues in a tissue-specific manner (Moll et al,
1982). Epithelial ovarian tumours are thought to arise from the
ovarian surface epithelium or mesothelium (Scully, 1979; Van
Niekerk et al, 1993). This hypothesis was supported by the pres-
ence ofthe so-called simple CKs 8 and 18 and, in greater amounts,
CKs 7 and 19 (Moll et al, 1991). As most ovarian and colon carci-
noma cell lines are derived from adenocarcinomas, differential
diagnosis may sometimes be difficult on the basis ofthe intraoper-
ative situation and the histopathological examination. The differ-
ence in the relative expression of CKs 7 and 20 was shown to be
helpful in the distinction between primary ovarian carcinomas and
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metastatic adenocarcinomas of the gastrointestinal tract to the
ovary (Wauters et al, 1995; Berezowski et al, 1996). CK20 has
been found throughout all colon carcinoma cell lines and has been
described as being the best marker for discriminating between
adenocarcinoma cell lines derived from ovarian carcinomas and
those derived from colon tumours (M6bus et al, 1994). The
present study was aimed at immunohistochemically analysing IF
expression, including that of CKs 7 and 20, in six newly estab-
lished ovarian carcinoma cell lines that were derived from solid
tumours. This study provides preliminary evidence for the expres-
sion ofCK20 in these ovarian carcinoma cell lines, irrespective of
their histological type.
MATERIALS AND METHODS
Cell lines
All the cell lines used were established from primary or metastatic
solid tumours of human ovarian cancer. Four cell lines, OVISE,
OVTOKO, OVMANA and OVSAYO, were derived from clear-cell
adenocarcinoma and the other two, OVSAHO and OVKATE, were
from serous papillary adenocarcinomas. The growth characteristics
of the six cell lines are summarized in Table 1. Each metastatic
tumour, from which OVISE, OVTOKO, OVSAHO or OVKATE
were derived, was histologically identical to the original tumour.
Morphological findings
The original tumour tissues, cultured on Lab Tek tissue chamber
slides (Nunc, Naperville, IL, USA) at different passages, and
xenografted tissues were fixed with 10% formaldehyde solution
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Table 1 Clinical and biological characteristics of the cell lines
Cell Initiation Source Histopathology Pretreatment Tumour-associated antigen
line of culture in serum
OVISE 1988.10 Solid Clearcell Six courses of CAP CA125, IAP
metastatic adenocarcinoma
OVTOKO 1990.7 Solid Clearcell Five courses of CAP CA125, IAP
metastatic adenocarcinoma TPA
OVSAHO 1991.1 Solid Serous papillary Fifteen courses of FAMT CAl 25
metastatic adenocarcinoma Six courses of CAP CA72-4
OVMANA 1991.1 Solid Clear cell Three courses of intraperitoneal CAl 25, CAl 9-9
primary adenocarcinoma cisplatin CA72-4, IAP, TPA
OVSAYO 1991.4 Solid Clear cell No CAl9-9, TPA
pnmary adenocarcinoma
OVKATE 1991.12 Solid Serous papillary Three courses of CAP CAl25, TPA
metastatic adenocarcinoma Three courses of EP
Survival of patients Median doubling Cell density CFE Tumorigenesis Current
(months) time (h) (cells cm-2) (%) in nude mice passage
s.c. i.p.
36 60 6.0 x 104 36.0 Yes No 246
2 70 6.0 x 104 45.0 Yes Yes 186
7 56 2.7 x 105 4.2 Yes Yes 112
1 67 1.9 x 105 ND Yes No 121
Alive 88 2.9x 105 27.2 No No 124
3 96 4.6x 105 0.3 Yes Yes 80
and stained with haematoxylin and eosin and periodic acid-Schiff.
The morphology of ten slides of histological sections and tissue
cultures and five slides of xenografted tissue sections were
examined with the aid of a light microscope.
Heterotransplantation in nude mice
Approximately 5 x 106 suspended cells were transplanted subcuta-
neously (s.c.) or intraperitoneally (i.p.) into Balb/c nude mice (6-
week-old male mice; Shizuoka Experimented Animal Co.,
Shizuoka, Japan). The tumours were examined histologically.
Antisera
The following monoclonal or polyclonal antibodies were used: (1)
MAb OV-TL12/30, specific for CK 7; (2) MAb 35BHII, raised
against CK8; (3) MAb DE-K13, raised against CK1O and CK13;
(4) MAb MNF116, raised against CKs 10, 17 and 18; (5) MAb E3,
raised against CK17; (6) MAb DC 10, raised against CK18; (7)
MAb RCK108, raised against CK19; (8) MAb BA17, raised
against CK19; (9) MAb Ks2O.8, raised against CK20; (10) MAb
V9, anti-vimentin; (11) MAb D33, anti-desmin; (12) MAb E29
(1), anti-epithelial membrane antigen (EMA); (13) anti-S-100
protein; (14) anti-human myoglobin; (15) MAb 1A4, anti-human
a-smooth muscle actin; (16) MAb 6F2, anti-human glial fibrillary
acidic protein; (17) MAb EGFR1, anti-EGF receptor; (18) MAb
K8.12, raised against CKs 13, 15 and 16; (19) MAb CY-90, raised
against CK18; (20) MAb VIM 13.2, anti-vimentin; (21) anti-type
II collagen; (22) MAb 528, anti-EGF receptor; (23) MAb
Ks6,KA12, raised against CK6; (24) MAb IT-Ks2O.3, raised
against CK20; (25) MAb IT-Ks2O.5, raised against CK20; (26)
MAb IT-Ks2O.10, raised against CK20; (27) MAbDE-K1O, raised
against CK1O; (28) MAb LLO02, raised against CK14; (29) MAb
CYFRA, raised against CK19. The biotinylated goat anti-mouse
immunoglobulin G, goat anti-rabbit immunoglobulin G and
avidin-conjugated horseradish peroxidase were purchased from
Nichirei Co. (Seikagaku Kohgyo Co., Tokyo, Japan).
Antisera (1)-{17) were purchased from Dakopatts (Dako Japan,
Kyoto, Japan); (18)-(20) were purchased from Sigma (Sigma-
Aldrich Co., Tokyo, Japan); (21) was purchased from Chemical
International (Funakoshi Co., Tokyo, Japan); (22) was purchased
from Oncogene Science (Cosmo Bio Co., Tokyo, Japan);
(23)-(26) were purchased from Progen Biotechnik (Heidelberg,
Germany); and (27) and (28) were purchased from Biomeda
(Foster City, CA, USA). Antiserum (29) was kindly provided by
Boehringer Mannheim (Tutzing, Germany).
Immunohistochemical procedure
Single labellingprocedure
The avidin-biotin peroxidase complex method described by Gorai
et al (1993) was used for single antigen localization. The single
labelling technique wasperformed atfourdifferent passages. Cells
cultured on coverslips (18 x 24 mm) were rinsed with phosphate-
buffered saline (PBS) and then fixed by immersion first in 70%
and then in 100% ethanol for 15 min each at -20°C, and then
dried. The coverslips were incubated for 30 min at room tempera-
ture with non-immune mouse or rabbit serum before staining with
one ofthe 10- to 1000-fold diluted primary antibodies for 30 min.
The coverslips were washed with PBS and then incubated for
30 min with secondary antibody. After additional washing with
PBS, the samples were incubated with avidin-conjugated horse-
radish peroxidase for 30 min. The coverslips were then washed
with PBS and reacted with a substrate containing 3,3-diaminoben-
zidine for5 min. Afterthey were washed inPBS, the sections were
dipped ten times into distilled water and then reacted with 0.5%
copper sulphate in normal saline for 5 min. After being dipped
several times in distilled water, counterstaining was performed
with haematoxylin. The slides were dehydrated in xylene and
embedded in synthetic resin.
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An immunohistochemical study of the original ovarian tumours
and heterotransplanted tumours was performed on formalin-fixed,
paraffin-embedded sections using the avidin-biotin-peroxidase
method, as described above. One representative block of each case
was deparaffinized andrehydrated ingraded alcohols. These sections
were incubated in 0.01 M citrate buffer at 95°C for 60 min. The
endogenous peroxidase activity was blocked with 0.3% hydrogen
peroxide in methanol. The primary antibody was applied for 60min
and was followed by incubation with secondary antibodies for
10 min, and then with an avidin-biotin-peroxidase complex reagent
for 10 min at room temperature. Sections were thoroughly washed
with PBS between steps. Sections were reacted by immersion in
Tris buffer containing 3,3-diaminobenzidine for5 min.
The staining ofthe positive control slides (ovarian carcinomas for
CK7 and colon carcinomas for CK20) was always positive and that
of the negative control slides was negative at each staining. The
expression oftheantigens isdefined as: -, negative; +, < 10% ofcells
positive; ++, 10-50% ofcells positive; +++, > 50% ofcells positive.
Double labelling procedure
For double labelling studies of CKs 7 and 20, streptavidin-biotin
labelling (Giorno, 1984) and alkaline phosphatase monoclonal
anti-alkaline phosphatase procedures (Malik and Daymon, 1982;
Cordell et al, 1984) were performed sequentially. The double
labelling technique was performed at three different passages.
After fixing and drying, the samples were first treated with normal
goat serum for 5 min at room temperature. The coverslips were
then incubated with one ofthe primary antisera, diluted 50- to 500-
fold with PBS, for20 min and then washed with PBS. The samples
were reacted with a biotinylated secondary goat anti-mouse anti-
body for 10 min and then washed with Tris buffer. The coverslips
were incubated with horseradish peroxidase-labelled streptavidin
for 10min, washed with Tris buffer and then reacted with 4-
chloronaphthol for 20 min, giving a blue end product. After they
were washed with PBS, the samples were incubated with 0.1 M
glycine chloride, pH 2.2, for 2 h and then washed again with PBS.
In the second alkaline phosphatase-anti-alkaline phosphatase
procedure, the samples were first incubated with a second primary
antiserum overnight at 4°C and washed with Tris buffer. The
coverslips were reacted with secondary rabbit anti-mouse antibody
for 30 min and then washed with Tris buffer. The samples were
reacted with mouse alkaline phosphatase-anti-alkaline phos-
phatase immune complex for 30 min and then washed with Tris
buffer. The coverslips were then reacted with substrates of naph-
thol AS-MX phosphate and Fast Red TR for 20 min, giving a red
end product. After counterstaining, the samples were embedded in
glycerin. For staining of the original tumours and heterotrans-
planted tumours, sections were prepared and reacted in the same
way as described for the single labelling procedure.
RESULTS
Heterotransplantation
The OVISE, OVTOKO, OVSAHO, OVMANA and OVKATE cells
produced 1.0-cm- to 1.5-cm-diameter tumours in the subcutis of
male Balb/c nude mice from 2-3 months after s.c. transplantation.
Histological examinationofthe tumours showedastructureofsheets
Table 2 Expression of intermediate filaments and other proteins in ovarian cancer cell lines
Cytokeratins
Cell lines Ks6, KA12 OV-TL12/30 35BH11 DE-K1O DE-K13 MNF116 K8, 12 LL002
CK6 CK7 CK8 CK10 CK10 and 13 CK10, 17 and 18 CK13,15 and 16 CK14
OVISE + ++ ++ - +++ +++
OVTOKO - + ++ - - +++ -
OVSAHO + ++ +++ +++ +
OVMANA + ++ - _ ++
OVSAYO + +++ +++ - +++ +++
OVKATE ++ +++ + + +++ +++
E3 DC10 CY-90 RCK108 BA17 CYFRA IT-Ks2O.3 IT-Ks2O.5 IT-Ks2O.10 Vimentin Desmin
CK17 CK18 CK18 CK19 CK19 CK19 CK20 CK20 CK20 V9 VIM13.2
_ +++ ... +++ +++ + + ++ -
++ ... + + .++ +++
_ +++ +++ + _+ - +++ +++ -
_ ++ ++ +++ ++ + __+ +++ ++ _
+ ... ... ++ + + ++ -
+ ++ +++ +++ + ++ + + _
EMA S-100 Myoglobin Collagen a-Smooth Glial fibrillary EGF-R
(type 11) muscle actin acidic protein 528 EGFRI (1)
+++ - - - - - ~~ ~~~~~~~~++ ++
+ -----+++ ++
++ ---__+ _
+-+ _
++ - - - < - +++ +++
++ -----+++ ++
As determined by immunohistochemistry: -, negative; +, < 10% of cells positive; ++, 10-50% of cells positive; +++, > 50% of cells positive.
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colour stains cytokeratin 7 (arrows) and red colour stains cytokeratin 20
(arrows). Scale bar = 50gim
Figure 1 Expression of cytokeratin 7 (arrows) (A) and 20 (arrows) (B) on
OVMANA cells. Scale bar = 100 gm
Figure 2 Expression of cytokeratin 20 on heterotransplanted tumour
(arrows) produced by OVKATE cells. Scale bar = 100 ,um
oftumour cells with clear cytoplasm (OVISE), a tubular structure of
tumour cells with clear eosinophilic cytoplasm (OVTOKO), sheets
or papillary structures of oval- to spindle-shaped atypical cells
Table 3 Expression of intermediate filaments in original ovarian tumours
Cytokeratins
Original OV-TL12/30 35BH11 CY-90 RCK108 Ks2O.8 IT-Ks20.10
tumours CK7 CK8 CK18 CK19 CK20 CK20
OVISE +++ + ++ +++ _ _
OVTOKO +++ - - - . _
OVSAHO + + + + - -
OVMANA + - ++ + _ _
OVSAYO + ++ - - - -
OVKATE +++ ++ + + - _
As determined by immunohistochemistry: -, negative; +, < 10% of cells
positive; ++, 10-50% of cells positive; +++, > 50% of cells positive.
Table 4 Expression of intermediate filaments in heterotransplanted tumours
Cytokeratins
Hetero- OV-TL12/30 35BH11 CY-90 RCK108 Ks2O.8 IT-Ks20.10
transplanted CK7 CK8 CK18 CY19 CK20 CK20
tumours
OVISE ++ + + ++ _ _
OVTOKO +++ - - - - -
ONSAHO + - + - - _
OVMANA ++ ++ ++ ++ + +
OVSAYO NT NT NT NT NT NT
OVKATE +++ + ++ + + +
As determined by immunohistochemistry: -, negative; +, < 10% of cells
positive; ++, 10-50% of cells positive; +++, > 50% of cells positive. NT not
tested.
(OVSAHO), atypical glandular structures lined with round cells
with clear or light cytoplasm (OVMANA) and solid nests or papil-
lary structures of oval- to spindle-shaped cells (OVKATE), which
resembled the original tumours from which the cell lines were
derived. The OVSAYO cells did not produce any s.c. tumours.
Intraperitoneal transplantation of OVTOKO, OVSAHO and
OVKATEcellsproducedmetastatic tumours and/ordissemination in
the peritoneal cavity.
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Patterns of intermediate filaments and other proteins
Cell lines
The six cell lines yielded various patterns of CK expression,
although the expressions of vimentin, desmin, EMA and other
proteins were identical in all of the cells (Table 2). The OVISE and
OVSAYO cells were positive for CKs 6, 7, 8, 18, 19 and 15 and/or
16 and were negative for CKs 10, 13, 14, 17 and 20. The
OVTOKO cells expressed CKs 7, 8, 18, 19 and 15 and/or 16 and
were negative for CKs 6, 10, 13, 14, 17 and 20. The OVSAHO
cells showed a reactivity to CKs 6, 7, 8, 14, 18, 19 and 15 and/or
16 and no reactivity to CKs 10, 13, 17 and 20. The OVMANA
cells were positive for CKs 6, 7, 8, 18, 19, 20 and 15 and/or 16, and
were negative for CKs 10, 13, 14 and 17 (Figure 1). The OVKATE
cells expressed CKs 6, 7, 8, 13, 17, 18, 19, 20 and 15 and/or 16,
and were negative for CKs 10 and 14. All the cells were positive
for vimentin, EMA and EGF receptors and were negative for
desmin, S-100, myoglobin, type II collagen, a-smooth muscle
actin and glial fibillary acidic protein. Positive staining for each
antigen in the six cell lines was identical at both early (10th
passage to 14th passage) and late (70th passage to 116th passage)
passages.
Original tumours
The original tumours yielded various patterns of CK expression.
All the tumours were positive for CK7 and negative for CK20. The
tumours of colon carcinoma expressed CK20. The tumours from
which OVISE, OVSAHO and OVKATE were established
expressed CKs 8, 18 and 19, whereas the tumour from which
OVTOKO was established was negative for these particular CKs
(Table 3).
Heterotransplanted tumour
The CK expression of the heterotransplanted tumours was similar
to that of the original tumours except for that of CK20. All the
tumours were positive for CK7, whereas the tumours consisting of
CK20-positive OVMANA and OVKATE cells were also positive
for CK20(Figure 2 and Table 4).
Double labelling
The double labelling technique showed that OVMANA and
OVKATE cell lines were composed of four types of cells: CK7-
positive, CK20-positive; CK7-positive, CK20-negative; CK7-
negative, CK20-positive; and CK7-negative, CK20-negative cells
(Figure 3). Furthermore, these four types of cells were observed in
the heterotransplanted tumours produced by OVMANA and
OVKATE cells. In contrast, two types of cell, CK7-positive,
CK20-negative, and CK7-negative, CK20-negative, were also
observed in the original ovarian tumours from which OVMANA
and OVKATE cells were derived.
DISCUSSION
Different human epithelium-derived cell lines have been shown to
produce tonofilaments containing different sets of CK polypeptides
(Franke et al, 1982). Most cell lines express three or four CK
polypeptides, including components 8 and 18. Some cell lines (for
example MCF-7 and HT-29) produce the small and acidic CK19,
which has been identified in some cell cultures (Fuchs and Green,
1981; Wu and Rheinwald, 1981). The most complex expression of
CK polypeptides has been observed in the cell line A-431, which is
derived from an epidermoid carcinoma of the vulva. The clonal
sublines of A-431 cell line continued to express as many as ten
different CK polypeptides (Moll et al, 1982). Five of the six cell
lines examined in the present study expressed at least six CK
polypeptides. OVKATE cells retained the ability to express as many
as nine CK proteins. This might reflect the multipotentiality of the
differentiation ofMullerian duct-derivedepithelia(Moll etal, 1991).
CK20 has only recently been introduced as a new CK polypep-
tide (Moll et al, 1990). CK20expression is almostentirely confined
to the mucosa of the small and large intestine, the gastric foveolar
epithelium, the umbrella cells of the urothelium and epidermal
Merkel cells (Moll et al, 1992). This specificity is maintained in the
corresponding tumours. In an immunohistochemical study, 89 out
of 92 cases of colorectal adenocarcinomas expressed CK20,
whereas 31 outof34 serous, endometrioid, anaplastic and clearcell
ovarian carcinomas were completely negative; the remaining three
were essentially negative for CK20 (Moll et al, 1992). CK20 has
been found in all colon carcinoma cell lines, but not in all ovarian
carcinoma cell lines (Mobus et al, 1994). CK20 was effective in
discriminating between metastatic andprimary ovarian carcinomas.
The only exception was agroup ofmucinous ovarian tumours (both
adenomas and carcinomas), which consistently expressed CK20,
irrespective of their degree of malignancy (Moll et al, 1992). This
sometimes made it difficult to differentiate between primary and
metastatic mucinous adenocarcinomas in the ovary.
In the study reported here (Table 2), CK20was expressed in one
clear-cell adenocarcinoma cell line and one serous papillary
adenocarcinoma cell line. To the best ofour knowledge, this is the
first report that demonstrates the expression of CK20 in ovarian
carcinoma cell lines without regard to their histological type. In
addition, CK20-positive cell lines expressed CK7 and vimentin. It
has been shown that the expression of simple epithelial CK7
occurs only in ovarian carcinoma cell lines and is completely
absent from colon carcinoma cell lines (Ramaekers et al, 1990;
Ueda et al, 1993; Mobus et al, 1994). However, CK7 staining was
found in ovarian metastatic tumours from primary gastric and
colonic adenocarcinomas (Wauters et al, 1995). An additional
differential marker is vimentin, which has been shown to be
strongly expressed in the ovarian carcinoma cell lines, but which is
essentially absent from the colon carcinoma cell lines (Viale et al,
1988; Coggi et al, 1989; Mobus et al, 1994; Gorai et al, 1995). The
tumours deriving CK20-positive cell lines have been considered to
be primary ovarian carcinoma, thus excluding the possibility of
metastasis ofcolon cancer to the ovary on the basis ofclinical and
histopathological findings, and a critical review of the original
histology by at least two independent pathologists.
CK20, however, was not expressed in the original ovarian
tumours from which the CK20-positive OVMANA and OVKATE
cell lines were derived, although CK20 was positive for colon
carcinomas. CK20 was expressed in the heterotransplanted
tumours produced by the CK20-expressing cell lines. It has been
reported that patterns of CK expression in cultured cells are not
decisively correlated with the CK present in the corresponding
tissue (Fuchs and Green, 1978, 1981; Sun and Green, 1978; Doran
et al, 1980; Wu and Rheinwald, 1981). The fact that CK20 was
newly expressed in ovarian carcinoma cells other than mucinous
tumours is of clinical importance when we consider the origin of
CK20-positive cells. It is possible that the patternofexpression is
altered during the establishment of cell lines. The regulatory
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control mechanisms ofCK20 expression in ovarian carcinoma cell
lines from CK20-negative ovarian tissues remain to be elucidated.
First, it may be that the loss of control mechanisms in individual
cells occurs, similar to the case for CKs 8 and 18 (Knapp and
Franke, 1989). In SV40-transformed fibroblasts, the CK18 gene
was constitutively transcribed into translatable mRNA but the
protein was rapidly degraded in the absence ofits complex partner,
CK8. Secondly, under certain conditions external environmental
factors may play an important role in modulating epithelial differ-
entiation. Cultured rabbit skin, corneal and oesophageal epithelial
cells have been shown to express more keratin proteins than were
originally present in intact tissues or observed in cysts formed by
cultured cells in athymic mice (Doran et al, 1980). Thirdly, a new
subclone arises from the descendants of the original transformed
cell and, with progressive growth in vitro, the cell population
becomes enriched with those variants that produce CK20
(Tannock, 1987). Some cholangiocarcinomas of the liver have
demonstrated a positive reactivity for CK20, whereas all non-
neoplastic bile ducts and ductules were negative, suggesting a
correlation between the CK20 expression and neoplastic transfor-
mation ofthe bile duct (Maeda et al, 1996).
In summary, six newly established human ovarian carcinoma
cell lines that were derived from solid tumours have been investi-
gated in terms oftheir immunohistochemical properties, including
IF expression. All six cell lines were positive for CKs 7, 8, 18 and
19. In the past, the expression of CK20 has been considered to be
entirely confined to the mucosa of the small and large intestine.
Although CK20 was not expressed in the original ovarian tumours,
two of the six cell lines (one clear-cell adenocarcinoma and one
serous papillary adenocarcinoma) expressed CK20, as did the
heterotransplanted tumours produced by those CK20-positive cell
lines. These cell lines will provide a relevant experimental system
for assessing the regulatory control mechanisms of IF expression,
including a family ofCKs.
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